- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Pharming Group N.V.: Pharming Group to convene Extraordinary General Meeting of Shareholders | 2 | GlobeNewswire (USA) | ||
| Di | Pharming Group N.V. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| Di | Pharming Group appoints former Novartis USA President Fabrice Chouraqui as New CEO | 11 | Seeking Alpha | ||
| Di | Pharming Group N.V.: Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer | 242 | GlobeNewswire (Europe) | Leiden, the Netherlands, January 21, 2025: Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Board of Directors has nominated Fabrice... ► Artikel lesen | |
| PHARMING GROUP NV ADR Aktie jetzt für 0€ handeln | |||||
| 15.01. | PHARMING TECHNOLOGIES B V: Offer document regarding Pharming Technologies B.V.'s recommended cash offer to the shareholders of Abliva AB (publ) | 5 | Cision News | ||
| 31.12.24 | Pharming Group (NASDAQ:PHAR) Trading 6.1% Higher - What's Next? | 4 | MarketBeat | ||
| 23.12.24 | Pharming Group (NASDAQ:PHAR) Trading 6.6% Higher - Should You Buy? | 6 | MarketBeat | ||
| 16.12.24 | Pharming pays $66M for Abliva and its 'potential blockbuster' mitochondrial disease med | 4 | FierceBiotech | ||
| 16.12.24 | Pharming Group offers to buy Sweden's Abliva for SEK 0.45/shr | 2 | Seeking Alpha | ||
| 16.12.24 | Pharming Group Offers To Acquire Abliva For SEK 0.45/shr In Cash | 3 | RTTNews | ||
| 15.12.24 | PHARMING TECHNOLOGIES B V: Pharming announces a recommended cash offer of SEK 0.45 per share to the shareholders of Abliva | 1 | Cision News | ||
| 15.12.24 | Pharming Group N.V.: Pharming announces public cash offer to the shareholders of Abliva AB | 570 | GlobeNewswire (Europe) | Proposed acquisition strengthens Pharming's late-stage pipeline with a potential first-in-disease asset
Abliva's lead product KL1333 is currently in a pivotal clinical trial, with a positive interim... ► Artikel lesen | |
| 11.12.24 | European Biotech Pharming Group Touts Positive Data From Pivotal Pediatric Study Of FDA-Approved Immune System Disorder Drug | 2 | Benzinga.com | ||
| 11.12.24 | Pharming Group N.V. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 11.12.24 | Pharming Group N.V.: Pharming announces positive topline data in pediatric clinical trial of leniolisib | 403 | GlobeNewswire (Europe) | Multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency
Data consistent with the improvements seen in the previously... ► Artikel lesen | |
| 09.12.24 | Critical Insights From Pharming Analyst Ratings: What You Need To Know | 7 | Benzinga.com | ||
| 29.10.24 | Original-Research: Pharming Group NV (von First Berlin Equity Research GmbH): Buy | 388 | dpa-AFX | Original-Research: Pharming Group NV - from First Berlin Equity Research GmbH 29.10.2024 / 14:51 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG. The issuer... ► Artikel lesen | |
| 28.10.24 | Oppenheimer cuts Pharming Group stock target, Outperform on Q3 results | 7 | Investing.com | ||
| 25.10.24 | Earnings call: Pharming Group NV reports growth amid CEO transition | 2 | Investing.com | ||
| 25.10.24 | Telefonkonferenz zu Geschäftsergebnissen: Pharming Group NV verzeichnet Wachstum | 2 | Investing.com Deutsch |
Seite:
1 2 3 Weiter >>
57 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HEIDELBERG PHARMA | 2,420 | -1,22 % | EQS-AFR: Heidelberg Pharma AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Heidelberg Pharma AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Heidelberg Pharma AG: Vorabbekanntmachung... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 10,735 | -1,01 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema | CAMBRIDGE, Mass., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,613 | +2,13 % | What Analysts Are Saying About Pacific Biosciences Stock | ||
| CENTOGENE | 0,120 | +20,00 % | Centogene NV: CENTOGENE Announces Voting Results of Extraordinary General Meeting | CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC: CNTGF) ("CENTOGENE" or the "Company"), the essential life science partner for data-driven answers... ► Artikel lesen | |
| ATAI LIFE SCIENCES | 1,529 | +5,78 % | Atai Life Sciences Appoints Gerd Kochendoerfer As COO; Srinivas Rao Assumes Sole CEO Role | ||
| PHARMING | 0,865 | -1,42 % | Pharming Group N.V.: Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer | Leiden, the Netherlands, January 21, 2025: Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Board of Directors has nominated Fabrice... ► Artikel lesen | |
| BIOMERIEUX | 112,70 | -0,53 % | Research and Markets: Europe Companion Diagnostics Market Analysis and Forecast, 2023-2033 with Competitive Analysis of Key Players - bioMerieux, F. Hoffmann-La Roche, ICON, and QIAGEN - ResearchAndMarkets.com | The "Europe Companion Diagnostics Market: Focus on Application, End User, Technology, and Country Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.
The... ► Artikel lesen | |
| CYCLACEL | 0,356 | +5,01 % | Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs | BERKELEY HEIGHTS, N.J., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative... ► Artikel lesen | |
| SYROS PHARMACEUTICALS | 0,194 | -3,96 % | Kia India Begins Production of Syros SUV | Kia Syros SUV records 10,258 pre-orders, continuing impressive momentum following world premiere in December 2024New family-focused SUV specifically designed for customers in IndiaGroundbreaking... ► Artikel lesen | |
| GENUS | 20,200 | -1,94 % | Wimex Group führt Genus Scale zur Befruchtungserkennung von Bruteiern ein | ||
| ANAPTYSBIO | 16,400 | +2,50 % | XFRA AN6: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 1,750 | +1,74 % | XTL BIOPHARMACEUTICALS LTD - 6-K, Report of foreign issuer | ||
| ABIONYX PHARMA | 1,204 | +0,33 % | ABIONYX Pharma Announces Its Financial Calendar for the Year 2025 | Regulatory News:
ABIONYX Pharma (FR0012616852 ABNX PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's... ► Artikel lesen | |
| MEIRAGTX | 5,700 | 0,00 % | MeiraGTx receives rare pediatric disease designation from FDA for its eye disease treatment | ||
| METABOLIC EXPLORER | 0,095 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 09.10.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 09.10.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 09.10.2024ISIN NameAU0000064966 VIRG.MON.... ► Artikel lesen |
Das Unternehmen PHARMING GROUP NV ADR kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 8,350 Euro und damit -1,76 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHARMING GROUP NV ADR finden Sie auf Wallstreet Online.
